Suppr超能文献

持续皮下胰岛素输注在预防 1 型糖尿病患者白蛋白排泄率增加方面比多次胰岛素皮下注射更有效。

Continuous subcutaneous insulin infusion is more effective than multiple daily insulin injections in preventing albumin excretion rate increase in Type 1 diabetic patients.

机构信息

Diabetes Unit, Hospital of Bergamo, A.O. Ospedali Riuniti Bergamo, Largo Barozzi, 1, Bergamo 24128, Italy.

出版信息

Diabet Med. 2009 Jun;26(6):602-8. doi: 10.1111/j.1464-5491.2009.02736.x.

Abstract

AIMS

To compare the effect of continuous subcutaneous insulin infusion (CSII) and multiple daily insulin injections (MDI) on albumin excretion rate (AER) in Type 1 diabetic patients.

METHODS

In a 3-year multicentre retrospective observational study, 110 Type 1 diabetic patients treated with CSII were compared with 110 patients treated with MDI matched at baseline for age, sex, diabetes duration and HbA(1c). At entry, 90 patients in each group had normal AER and 20 persistent microalbuminuria. AER, estimated glomerular filtration rate (eGFR), HbA(1c,) lipids and blood pressure were assessed.

RESULTS

HbA(1c) was lower in the CSII than in the MDI group (8.1 +/- 0.9 vs. 8.4 +/- 1.3%; P < 0.005 after 3 years). Blood pressure and eGFR were similar during the study. AER [median (95% confidence interval)], similar at baseline [6.0 microg/min (9, 21) in the CSII group vs. 4.4 (8, 16) in the MDI group, NS] was significantly lower in the patients treated with CSII both at year 2 and at year 3 of follow-up [4.7 microg/min (6, 12) vs. 6.4 (13, 29), P < 0.002]. This difference was observed even when normo- and microalbuminuric patients were analysed separately. Nine patients progressed to microalbuminuria in the MDI group and only one in the CSII group. Nine patients regressed to normoalbuminuria in the CSII group, whereas only two regressed to normoalbuminuria in the MDI group.

CONCLUSIONS

Despite a small benefit in terms of improved glycaemic control, CSII therapy may be useful in decreasing the progressive increase in AER in Type 1 diabetic patients.

摘要

目的

比较连续皮下胰岛素输注(CSII)和多次皮下胰岛素注射(MDI)对 1 型糖尿病患者白蛋白排泄率(AER)的影响。

方法

在一项为期 3 年的多中心回顾性观察研究中,将 110 例接受 CSII 治疗的 1 型糖尿病患者与在年龄、性别、糖尿病病程和糖化血红蛋白(HbA1c)方面相匹配的 110 例接受 MDI 治疗的患者进行比较。入组时,每组各有 90 例患者 AER 正常,20 例患者持续微量白蛋白尿。评估 AER、估计肾小球滤过率(eGFR)、HbA1c、血脂和血压。

结果

CSII 组的 HbA1c 低于 MDI 组(8.1±0.9 比 8.4±1.3%;3 年后 P<0.005)。研究期间血压和 eGFR 相似。AER[中位数(95%置信区间)],基线时相似[CSII 组 6.0μg/min(9,21)比 MDI 组 4.4μg/min(8,16),NS],在 CSII 组的患者在第 2 年和第 3 年的随访中明显更低[4.7μg/min(6,12)比 6.4μg/min(13,29),P<0.002]。即使在正常白蛋白尿和微量白蛋白尿患者中分别进行分析时,也观察到了这种差异。9 例患者在 MDI 组进展为微量白蛋白尿,而 CSII 组仅 1 例。9 例患者在 CSII 组回归为正常白蛋白尿,而 MDI 组仅有 2 例回归为正常白蛋白尿。

结论

尽管在改善血糖控制方面有较小的益处,但 CSII 治疗可能有助于减少 1 型糖尿病患者 AER 的进行性增加。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验